Stock Track | Corcept Therapeutics Soars 25.20% in 24 Hours as Q2 Earnings Massively Beat, Guidance Raised

Stock Track07-30

Corcept Therapeutics (CORT) shares skyrocketed 25.20% over the past 24 hours, with the bulk of the gain coming in after-hours trading following the company's second-quarter earnings release. The stock surged as investors cheered results that crushed Wall Street expectations.

The dramatic move was fueled by a massive earnings beat. Corcept reported Q2 earnings per share of $0.36, far above the analyst consensus estimate of approximately $0.00 to $0.02. Revenue climbed 31.7% year-over-year to $256.1 million, easily surpassing the Street estimate of around $220 million. The strong performance was driven by the continued commercial success of its flagship product Korlym and the successful launch of newly approved Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March.

Adding to the bullish sentiment, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from the prior forecast of $950 million to $1.05 billion and well above the FactSet consensus estimate of $999.5 million. The company also highlighted progress in its pipeline, including the resubmission of its New Drug Application for relacorilant for Cushing's syndrome, with an FDA decision expected by December 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143312161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 08:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143312161","market":"us","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Soars 25.20% in 24 Hours as Q2 Earnings Massively Beat, Guidance Raised","media":"Stock Track","content":"<p>Corcept Therapeutics (CORT) shares skyrocketed 25.20% over the past 24 hours, with the bulk of the gain coming in after-hours trading following the company's second-quarter earnings release. The stock surged as investors cheered results that crushed Wall Street expectations.</p><p>The dramatic move was fueled by a massive earnings beat. Corcept reported Q2 earnings per share of $0.36, far above the analyst consensus estimate of approximately $0.00 to $0.02. Revenue climbed 31.7% year-over-year to $256.1 million, easily surpassing the Street estimate of around $220 million. The strong performance was driven by the continued commercial success of its flagship product Korlym and the successful launch of newly approved Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March.</p><p>Adding to the bullish sentiment, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from the prior forecast of $950 million to $1.05 billion and well above the FactSet consensus estimate of $999.5 million. The company also highlighted progress in its pipeline, including the resubmission of its New Drug Application for relacorilant for Cushing's syndrome, with an FDA decision expected by December 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Soars 25.20% in 24 Hours as Q2 Earnings Massively Beat, Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Soars 25.20% in 24 Hours as Q2 Earnings Massively Beat, Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-30 08:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corcept Therapeutics (CORT) shares skyrocketed 25.20% over the past 24 hours, with the bulk of the gain coming in after-hours trading following the company's second-quarter earnings release. The stock surged as investors cheered results that crushed Wall Street expectations.</p><p>The dramatic move was fueled by a massive earnings beat. Corcept reported Q2 earnings per share of $0.36, far above the analyst consensus estimate of approximately $0.00 to $0.02. Revenue climbed 31.7% year-over-year to $256.1 million, easily surpassing the Street estimate of around $220 million. The strong performance was driven by the continued commercial success of its flagship product Korlym and the successful launch of newly approved Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March.</p><p>Adding to the bullish sentiment, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from the prior forecast of $950 million to $1.05 billion and well above the FactSet consensus estimate of $999.5 million. The company also highlighted progress in its pipeline, including the resubmission of its New Drug Application for relacorilant for Cushing's syndrome, with an FDA decision expected by December 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1143312161","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143312161","pubTimestamp":1785370174,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics (CORT) shares skyrocketed 25.20% over the past 24 hours, with the bulk of the gain coming in after-hours trading following the company's second-quarter earnings release. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"股票跟踪 | Corcept Therapeutics 第二季度盈利大幅超出预期，指引上调，24 小时内飙升 25.20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (CORT) shares skyrocketed 25.20% over the past 24 hours, with the bulk of the gain coming in after-hours trading following the company's second-quarter earnings release. The stock surged as investors cheered results that crushed Wall Street expectations.The dramatic move was fueled by a massive earnings beat. Corcept reported Q2 earnings per share of $0.36, far above the analyst consensus estimate of approximately $0.00 to $0.02. Revenue climbed 31.7% year-over-year to $256.1 million, easily surpassing the Street estimate of around $220 million. The strong performance was driven by the continued commercial success of its flagship product Korlym and the successful launch of newly approved Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March.Adding to the bullish sentiment, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from the prior forecast of $950 million to $1.05 billion and well above the FactSet consensus estimate of $999.5 million. The company also highlighted progress in its pipeline, including the resubmission of its New Drug Application for relacorilant for Cushing's syndrome, with an FDA decision expected by December 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143312161","isCrawlerRequest":true}